Chronic Myeloid Leukemia

Fecal Occult Blood Test, Colonoscopy Useful for Detecting Dasatinib-induced Colitis

Fecal Occult Blood Test, Colonoscopy Useful for Detecting Dasatinib-induced Colitis

By

Researchers examined the frequency of TKI-induced hemorrhagic colitis among patients with CML treated with dasatinib and evaluated the efficacy of screening with a fecal occult blood test followed by colonoscopy in this patient population.

Ibrutinib Effective as Salvage Therapy in Relapsed CLL Following Allogeneic HSCT

Ibrutinib Effective as Salvage Therapy in Relapsed CLL Following Allogeneic HSCT

By

A report of an evaluation of the benefit of ibrutinib in relapsed CLL following allogeneic HSCT based on an analysis of data from patients with relapsed CLL who received ibrutinib salvage therapy after allogeneic HSCT.

Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response

Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response

By

In patients with chronic myeloid leukemia in chronic phase, prolonged treatment with imatinib helps to achieve a deeper molecular response over 5 years.

Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia

Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia

By

Inhibition of the protein Ezh2 causes chronic myelogenous leukemia (CML) stem cells to die. Adding drugs that target this protein to imatinib (Gleevec) or other BCR-ABL blockers could result in a cure for this disease.

EUTOS Registry Represents Benchmark for Evaluation of New CML Treatments

EUTOS Registry Represents Benchmark for Evaluation of New CML Treatments

By

The population-based EUTOS registry demonstrated high overall and progression-free survival rates among patients with chronic myeloid leukemia.

CML-CP: Dasatinib, Nilotinib Associated With Similar Survival Outcomes as Frontline Therapy

CML-CP: Dasatinib, Nilotinib Associated With Similar Survival Outcomes as Frontline Therapy

By

Dasatinib and nilotinib are associated with similar response rates and survival outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP).

Social Support Crucial for Patients With CML Receiving Lifelong Targeted Therapy

Social Support Crucial for Patients With CML Receiving Lifelong Targeted Therapy

By

For patients with chronic myeloid leukemia treated with lifelong targeted therapies, social support is crucial for maintaining psychological well-being.

Tyrosine Kinase Inhibitor Therapy Can Be Safely Stopped in Select Patients With CML in Chronic Phase

Tyrosine Kinase Inhibitor Therapy Can Be Safely Stopped in Select Patients With CML in Chronic Phase

By

A high percentage of patients with CML treated with TKIs achieve deep molecular responses and can safely stop therapy. Initials results of the EURO-SKI trial define prognostic markers that indicate durability of deep molecular responses after stopping TKI therapy.

Life Expectancy of Patients With CML Approaching That of General Population

Life Expectancy of Patients With CML Approaching That of General Population

By

In the era of tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation, the life expectancy of patients with CML is approaching that of the general population.

Post-transplant Maintenance TKIs Beneficial for Patients With High-risk Ph+ Leukemia

Post-transplant Maintenance TKIs Beneficial for Patients With High-risk Ph+ Leukemia

By

A study examined the impact of post-transplant maintenance TKIs on patients with Ph+ acute lymphoblastic leukemia and chronic myeloid leukemia.

Efficacy of First-line Ponatinib in CP-CML Remains Unclear

Efficacy of First-line Ponatinib in CP-CML Remains Unclear

By

Ponatinib treatment was compared with imatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CP-CML).

Significant Reduction in Treatment Costs Are Anticipated With the Emergence of Generic TKI

Significant Reduction in Treatment Costs Are Anticipated With the Emergence of Generic TKI

By

With the January 2016 expiration of the patent on Gleevac, significant cost savings can be realized by insurance companies and patients. Just 15 years ago, Gleevac (imatinib) changed chronic myeloid leukemia (CML) from a fatal disease to a treatable illness.

Advice for Patients With CML Traveling While On Oral Chemotherapy

Advice for Patients With CML Traveling While On Oral Chemotherapy

By

During the summer, many patients with CML who are taking oral chemotherapy drugs have questions about taking their drugs while traveling. What advice can we give them regarding this?

Lymphocytosis Associated With Improved Survival in Dasatinib-treated Patients

Lymphocytosis Associated With Improved Survival in Dasatinib-treated Patients

By

Lymphocytosis is associated with higher response rates, significantly longer response durations, and improved overall survival.

Dasatinib, Nilotinib, Ponatinib Increase Vascular Occlusive Events

Dasatinib, Nilotinib, Ponatinib Increase Vascular Occlusive Events

By

Dasatinib, nilotinib, and ponatinib, used in the treatment of patients with chronic myeloid leukemia (CML) increase vascular occlusive events.

Ponatinib Ups Overall Survival in Patients with CP-CML and T315I Mutation

Ponatinib Ups Overall Survival in Patients with CP-CML and T315I Mutation

By

For patients with chronic phase chronic myeloid leukemia (CP-CML) and the T315I mutation, ponatinib treatment may offer longer overall survival.

TKI Withdrawal Linked to Osteoarticular Pain

TKI Withdrawal Linked to Osteoarticular Pain

By

Nearly 25 percent of patients with chronic myeloid leukemia (CML) undergoing treatment with tyrosine kinase inhibitors are vulnerable to a a "withdrawal syndrome," a recent study reported.

For Best Responses, Use Therapeutic Drug Monitoring to Individualize Daily Imatinib

For Best Responses, Use Therapeutic Drug Monitoring to Individualize Daily Imatinib

By

Research indicates that adjustment of imatinib doses based on therapeutic drug monitoring can result in higher rates of major molecular response in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.

In CP-CML, Deep Molecular Responses to TKIs Result from Immune Suppressor Activity

In CP-CML, Deep Molecular Responses to TKIs Result from Immune Suppressor Activity

By

New research indicates that patients with chronic-phase chronic myeloid leukemia with deep molecular responses to TKIs have increased effector natural killer and cytotoxic T cell immune responses to leukemia-associated antigens.

Study Assesses Factors Influencing Bosutinib Efficacy, Safety in CML

Study Assesses Factors Influencing Bosutinib Efficacy, Safety in CML

By

Bosutinib continues to demonstrate durable long-term efficacy and manageable toxicity in patients with chronic myeloid leukemia (CML).

Adding Pioglitazone to Imatinib May Improve Treatment of Chronic Myeloid Leukemia

Adding Pioglitazone to Imatinib May Improve Treatment of Chronic Myeloid Leukemia

Patients with chronic myeloid leukemia who received imatinib plus pioglitazone achieved a sustained complete molecular response for up to 4.7 years after the withdrawal of the antidiabetes medication.

TKIs Appear Safe in Patients With Chronic Myeloid Leukemia, CKD

TKIs Appear Safe in Patients With Chronic Myeloid Leukemia, CKD

Tyrosine kinase inhibitors (TKIs) seem safe in patients with chronic myeloid leukemia (CML) in chronic-phase and chronic kidney disease.

Use of Pharmacokinetics to Measure Response in CML

Use of Pharmacokinetics to Measure Response in CML

By

What data are available concerning inter- and intrapatient variability in the pharmacokinetics of TKIs in chronic myeloid leukemia?

A roundup of FDA oncology news from October 2013

By

The FDA asked the manufacturer of ponatinib (Iclusig) to suspend marketing and sales of the drug, hydrocodone bitartrate extended-release capsules (Zohydro ER) gained FDA approval, and other FDA actions.

Genetic Details of Leukemia Resistance

By

Two gene alterations pair up to promote the growth of leukemia cells and their escape from anticancer drugs, according to new research.

QOL Issues Affect Patients With CML Taking Oral Chemotherapy

By

Patients with chronic myeloid leukemia (CML) who are treated with tyrosine kinase inhibitors (TKIs) have significant side effects and QOL issues that need to be addressed.

In CNL and Atypical CML, mutations in CSF3R are common

In CNL and Atypical CML, mutations in CSF3R are common

For patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia, activating mutations in the gene encoding the colony stimulating factor 3 receptor are common.

High costs of leukemia may be harming patients

By

The increasing cost of treatments for chronic myeloid leukemia in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care.

Leukemia arsenal has new drugs

Ponatinib (Iclusig), bosutinib (Bosulif), and omacetaxine (Synribo) are enhancing treatment for persons with certain forms of leukemia.

DNA-repair problems destroy hardy leukemia cells

Leukemia stem cells that overcome drug therapy can be thwarted when deprived of RAD52, a protein key to DNA repair of these cancer cells.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs